Why Viking Therapeutics Stock Popped Again Today
Shares of Viking Therapeutics (NASDAQ: VKTX) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts.
Viking stock inched higher Monday after Truist Securities analyst Joon Lee lowered his price target, while predicting the company will benefit from phase 3 clinical trial news on its new VK2735 weigh loss drug. Today, the shares are advancing by leaps and bounds on an even more positive endorsement from Cantor Fitzgerald's Steven Seedhouse, who says the stock is a buy, and predicts the $29 price will roughly quadruple to hit $104 within a year.
Seedhouse doesn't beat around the bush: "Our thesis is entirely focused on lead [injectable] drug, VK2735, a GLP-1/GIP dual agonist entering phase 3 development for general obesity."
Source Fool.com
Viking Therapeutics Inc Stock
Our community is currently high on Viking Therapeutics Inc with 5 Buy predictions and 0 Sell predictions.
With a target price of 65 € there is potential for a 132.18% increase which would mean more than doubling the current price of 28.0 € for Viking Therapeutics Inc.
